XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
| Status: | Archived |
|---|---|
| Conditions: | Angina, Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2010 |
| End Date: | August 2013 |
This is a prospective, randomized, active-controlled, open label, parallel two-arm,
multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER
SELECT PLUS Sirolimus-Eluting Coronary Stent System (SECSS) ("CYPHER SELECT PLUS") during
commercial use in China.
Objectives
- Confirm the safety and effectiveness of the XIENCE V EECSS for the treatment of
patients in China
- Evaluate patient compliance with dual antiplatelet therapy (DAPT)
- Evaluate physician-determined XIENCE V EECSS acute performance, deliverability, and
resource utilization
We found this trial at
1
site
Click here to add this to my saved trials
